Breaking News, Collaborations & Alliances

GSK, Angiochem in Development Pact

Angiochem is eligible to receive as much as $300 million for LSD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline (GSK) and Angiochem have entered a global collaboration to discover, develop and commercialize treatments for lysosomal storage diseases (LSDs). The collaboration will leverage Angiochem’s expertise in creating novel therapeutics that cross the blood-brain barrier (BBB) with GSK’s scientific, development and commercialization capabilities in rare diseases.   Angiochem will initially create and develop an enzyme replacement therapy for a specified LSD and GSK will have the right t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters